Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bisphosphonates and bone metastases].

A Lortholary1, E Jadaud, P Berthaud

  • 1Centre Paul-Papin, 2, rue Moll, 49033 Angers.

Bulletin Du Cancer
|October 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

The COVID-19 pandemic reduced delays in the care pathway for patients with glioma at a French institute.

Revue neurologique·2025
Same author

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

Gynecologic oncology·2020
Same author

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Bisphosphonates effectively manage bone pain and reduce skeletal events in cancer patients. Further research is needed to explore their role in preventing bone metastases before they appear.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Bisphosphonates are potent inhibitors of bone resorption.
  • They emerged as standard treatment for tumor-induced hypercalcemia in the 1990s.
  • Early studies showed efficacy in reducing bone pain, fractures, and hypercalcemia.

Purpose of the Study:

  • To review the efficacy of bisphosphonates in managing bone metastases from various cancers.
  • To assess their role in palliative care and potential in adjuvant settings.
  • To evaluate the impact of newer bisphosphonates like zoledronate.

Main Methods:

  • Review of uncontrolled phase II and randomized phase III studies.
  • Analysis of data from multiple myeloma, breast cancer, and prostate cancer patient cohorts.

Related Experiment Videos

  • Comparison of bisphosphonate treatments against placebo and assessment of survival duration.

    • Main Results:

    • Bisphosphonates decreased bone events and pain in multiple myeloma and breast cancer.
    • Studies in breast cancer showed bisphosphonates superior to placebo for pain and bone events, but not survival.
    • Efficacy in prostate cancer bone metastases requires further investigation.

    Conclusions:

    • Bisphosphonates are crucial for palliative care in breast cancer and multiple myeloma with bone metastases.
    • They are considered standard therapy for painful bone lesions in myeloma, breast, and prostate cancer.
    • Further adjuvant bisphosphonate studies are needed, especially with potent agents like zoledronate.